Isomaltulose

Other Names

(3S,4R,5R)-1,3,4,5-Tetrahydroxy-6-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)hexan-2-one(3S,4R,5R)-1,3,4,5-tetrahydroxy-6-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}hexan-2-one6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose6-O-alpha-D-glucopyranosyl-D-fructofuranose6-O-alpha-D-glucopyranosyl-D-fructose6-O-α-D-glucopyranosyl-D-fructofuranose6-O-α-D-glucopyranosyl-D-fructoseD-Fructose, 6-O-α-D-glucopyranosyl-isomaltulose anhydrousisomaltulose monohydratepalatinoseα-D-glucopyranosyl-1,6-D-fructofuranose

Synopsis

Isomaltulose (Palatinose): A Comprehensive Reference

1. Identity and Chemical Characterization

Names and Classification

Isomaltulose (trade name Palatinose, chemical name 6-O-α-D-glucopyranosyl-D-fructose) is a disaccharide carbohydrate composed of glucose and fructose. It is also designated by its systematic IUPAC name 6-O-(α-D-glucopyranosyl)-D-fructofuranose, and is catalogued under CAS number 13718-94-0. Isomaltulose is a naturally occurring disaccharide composed of alpha-1,6-linked glucose and fructose monomers. Isomaltulose is an isomer of sucrose (commonly known as table sugar), sharing the same chemical formula (C₁₂H₂₂O₁₁).

Structural Distinction from Sucrose

Chemically, isomaltulose is known as 6-O-α-D-glucopyranosyl-D-fructofuranose and contains an α-1,6 glycosidic bond instead of the α-1,2 bond found in its isomer sucrose. This seemingly small difference in bonding position has profound physiological consequences: like sucrose, isomaltulose can be digested to glucose and fructose; however, while in sucrose the glucose is linked to the anomeric carbon of the fructose (an α-1,2 glycosidic linkage), in isomaltulose the linkage is to the 6 carbon (α-1,6), making isomaltulose a reducing sugar, unlike sucrose.

Physical Properties

Isomaltulose is a disaccharide with a chemical formula of C₁₂H₂₂O₁₁ and a molar mass of 342.30 g·mol⁻¹. Commercially, it is available as a white, crystalline powder. It has low hygroscopicity, meaning it has very low moisture absorption. Its melting point is 123–128 °C. Isomaltulose resembles the taste and physical properties of sucrose but isomaltulose is half as sweet, and provides the same amount of energy as sucrose (i.e., 4 kcal/g).

Isomaltulose has very low moisture absorption (hygroscopy), giving it free-flowing properties in instant powders, which because of their low risk of lumping can easily be used in drinks and other instant products. It is highly stable during processing, including acidic conditions and environments where bacteria might grow.

Natural Sources

Isomaltulose is a reducing disaccharide consisting of a glucose molecule and a fructose molecule. It is naturally occurring in honey in levels up to 1% and can also be found in extracts of sugar cane. In nature, isomaltulose and trehalulose exist in honey and sugar cane in very small quantities.

Industrial Production

Isomaltulose, also known by the trade name Palatinose, is manufactured by enzymatic rearrangement (isomerization) of sucrose from beet sugar. The enzyme isomaltulose synthase from the bacterium Protaminobacter rubrum is used to turn sucrose into isomaltulose. Industrial bioconversion of sucrose to isomaltulose happens through the enzymatic activity of sucrose isomerases from numerous microorganisms. Isomaltulose is hydrogenated to produce isomalt, a minimally digestible carbohydrate that is used as a sugar replacer, for example in sugar-free candies and confectionery.

Common Commercial Forms and Preparations

Isomaltulose finds application in baked goods, pastry glazings and icings, breakfast cereals, cereal bars, dairy produce, sugar confectionery (e.g., chocolates, jellies, chewy confections and chewing or bubble gum), frozen desserts, fruit-juice beverages, malt beverages, sports beverages, energy drinks, instant drinks, and special and clinical nutrition feeds. Analytical methods for characterization and assay of commercial isomaltulose are laid down, for example, in the Food Chemicals Codex.

2. History and Discovery

Scientific Discovery

Isomaltulose, a disaccharide isomer of sucrose, was first observed in 1952 during experiments on dextran synthesis from sucrose using the bacterium Leuconostoc mesenteroides, and it was subsequently named palatinose in 1957 by researchers investigating bacterial sucrose metabolism. This discovery occurred in the context of sucrose processing studies, where microbial enzymes were found to rearrange the glycosidic linkage in sucrose from α-1,2 to α-1,6.

Isomaltulose was first described in 1954, when US Department of Agriculture (USDA) scientists isolated it from dextran production broths during the enzymatic conversion of sucrose to dextran. Isomaltulose was also found during a German study of bacterial contamination occurring in a sugar factory, as described in articles by Silvia Lorenz in Z. Zuckerind. (1958).

Industrial and Commercial History

In the mid-1950s, Professor Weidenhagen, then head of the central laboratory at Südzucker, discovered the bacterium P. aminobacter rubrum and began to study it more closely. The bacterium releases an enzyme that helps it form a new type of sugar from sucrose molecules: isomaltulose. This naturally occurring process secures a "food source" that is only available to this bacterium. At the time, developers considered this an undesirable effect, as it reduced the quality and expected sweetness of the sucrose. However, researchers quickly recognised its potential. In 1956, they patented isomaltulose as Palatinose™, anticipating its future use as a novel sugar.

The initial introduction of isomaltulose in foods began in Japan and other parts of Asia. The brand name Palatinose™, under which it is commercially available today, reflects its origin in the Palatinate region of Germany. Isomaltulose has been used as an alternative to sugar in foods in Japan since 1985, in the EU since 2005, in the US since 2006, and in Australia and New Zealand since 2007, besides other countries worldwide.

Note on traditional use: Isomaltulose as a purified or isolated compound has no documented traditional use in any formal ethnobotanical or medical tradition. Its natural sources — honey and sugarcane — have extensive histories of traditional use across many cultures and time periods, but the specific compound isomaltulose was not known to, or intentionally employed by, pre-modern practitioners. The compound's relevance to health is an entirely modern, laboratory-derived finding dating from the second half of the twentieth century.

3. Key Constituents and Mechanisms of Action

Structural Basis for Slow Digestion

The University of Sydney reported that isomaltulose has a glycemic index of 32, classified as very low, and provides sustained energy without abrupt glucose fluctuations. Its hydrolysis in the small intestine occurs four to five times more slowly than that of sucrose, prolonging energy release. The slow hydrolysis is directly attributable to the α-1,6 glycosidic linkage, which is cleaved more slowly by intestinal disaccharidases than the α-1,2 bond of sucrose.

Complete Intestinal Absorption

Isomaltulose is an available carbohydrate like sucrose and most other sugars or maltodextrins, in the sense that it is fully metabolised in the small intestine, and does not enter the large intestine. The complete hydrolysis of isomaltulose in the small intestine has been further demonstrated in urinary excretion studies, confirming that its breakdown products, glucose and fructose, are fully metabolized and absorbed.

Incretin and Hormonal Responses

Due to its binding, isomaltulose is slowly hydrolysed, which results in a rather weak postprandial glycemic-insulinemic response, accompanied by a minimal GIP (glucose-dependent insulinotropic polypeptide) secretion and a stimulated secretion of GLP-1 (glucagon-like peptide-1). This hormonal profile — lower GIP and higher GLP-1 — distinguishes isomaltulose from high-GI sugars and is associated with a more favorable metabolic milieu.

Fat Oxidation Promotion

This effect is attributed to the lowering effect of isomaltulose on blood glucose and insulin levels compared to readily available high-glycemic carbohydrates. Lower postprandial insulinemia suppresses the inhibition of lipolysis and fat oxidation, thereby shifting the metabolic substrate mix toward greater fat utilization during the postprandial period and during exercise.

Dental Non-Cariogenicity

Fermentation of carbohydrates by bacteria in the mouth (especially on the teeth) is responsible for the formation of dental plaque and oral acids. The acid initiates tooth demineralisation and tooth decay (dental caries). Isomaltulose largely resists fermentation by oral bacteria and is the first carbohydrate of its kind with negligible acid production on teeth, as shown by pH telemetry.

4. Scientific Evidence by Area of Use

4.1 Glycemic and Insulinemic Response

The low glycemic properties of isomaltulose have been studied extensively. Data are available from over 30 human intervention trials comparing the blood glucose response of isomaltulose with that of sucrose or other traditional readily available carbohydrates.

A 2022 systematic review and meta-analysis published in Advances in Nutrition (registered in PROSPERO as CRD42021290396) systematically synthesized the RCT evidence. Researchers systematically searched PubMed, Embase, and the Cochrane Library for randomized controlled trials (RCTs) prior to October 2021. RCTs were eligible if they enrolled adults to oral intake of isomaltulose or other carbohydrates dissolved in water after an overnight fast and compared their 2-h postprandial glucose and insulin concentrations. Isomaltulose ingestion was associated with slower increases in the circulating glucose and insulin concentrations and slower decreases after the peak than sucrose ingestion. The peak concentrations of glucose (P = 0.0016) and insulin (P = 0.0017) following isomaltulose ingestion were much less than those following sucrose ingestion.

However, the authors noted important caveats: evidence regarding the effect of isomaltulose on glycemic and insulinemic responses is still conflicting, which limits isomaltulose's application in glycemic management. Low-to-moderate levels of evidence suggest there may be more benefit of isomaltulose for people with type 2 diabetes, impaired glucose tolerance, or hypertension; older people; overweight or obese people; and Asian people.

A separate 2025 meta-analysis focused specifically on diabetic populations. Ten studies were included, involving 367 participants. The meta-analysis showed that isomaltulose significantly reduced plasma glucose level at 60 min post-meal, though the actual effect could be modest in terms of clinical relevance compared to sucrose (MD: −7.99, 95% CI: −8.58, −7.39, p < 0.00001). Notable variability in the study results was observed, which may be attributed to multiple factors such as participant demographics and meal composition. The findings are supportive for the use of isomaltulose as a beneficial dietary alternative to sucrose for managing postprandial glycemic levels in diabetic patients.

An early landmark study from Japan (1985) at the University of Tsukuba provided foundational human data: plasma glucose following isomaltulose ingestion rose gradually over 60 minutes to 110.9 mg/dl and then remained stable for two hours. By contrast, sucrose ingestion produced a rapid peak of 143.3 mg/dl within 30 minutes, followed by a sharp decline. These results were consistent even among individuals with diabetes, supporting isomaltulose as a suitable sweetener for this population.

4.2 Preoperative Carbohydrate Loading in Surgical Patients

A randomized controlled trial published in 2025 investigated preoperative oral isomaltulose in patients with type 2 diabetes mellitus undergoing surgery. At 24 hours postoperatively, the isomaltulose group exhibited significantly lower HOMA-IR (6.89 ± 3.38 vs. 11.60 ± 4.34; mean difference = 4.71, 95% CI 2.70–6.72, p < 0.001) and serum insulin levels (15.59 ± 5.58 vs. 24.54 ± 5.92 mU/L; mean difference = 8.94, p < 0.001). Although overall blood glucose was higher, glycemic variability was significantly better (20.54% vs. 27.95%, p < 0.001). In well-controlled T2DM patients, preoperative oral isomaltulose was associated with lower postoperative insulin resistance and reduced glycemic variability, without delaying gastric emptying. These metabolic benefits were accompanied by a transient elevation in pre-induction blood glucose, which should be weighed in clinical decision making.

4.3 Sports Performance and Fat Oxidation

The slow-release as well as the low glycemic and low insulinemic properties of isomaltulose have been of particular interest for applications in the area of sports nutrition and cognitive performance.

A study published in The Journal of Nutrition was among the first to compare exogenous oxidation of isomaltulose versus sucrose during moderate-intensity exercise in men. Whereas many chemical and biochemical characteristics of isomaltulose were well documented, limited information was available on the impact of oral isomaltulose during endurance exercise on carbohydrate and fat oxidation. The primary goal was to compare the blood substrate responses and the exogenous oxidation rates of two oral disaccharides, sucrose and isomaltulose, during moderately intense exercise.

A double-blind, randomised, cross-over trial in 21 male recreational endurance runners (published in the Journal of the International Society of Sports Nutrition, 2021) examined isomaltulose relative to glucose and maltodextrin. Twenty-one male recreational endurance runners performed a 70-min constant load trial at 70% maximal running speed (Vmax), followed by a time to exhaustion (TTE) test at 85% Vmax after ingesting either 50 g isomaltulose, maltodextrin or glucose. Isomaltulose ingestion appeared to have a more advantageous effect on blood glucose, insulin and GIP response compared to maltodextrin and glucose, as was shown by reduced postprandial absolute concentrations and a lower rate of fluctuation during treadmill running exercise. However, glucose availability, as well as fat and carbohydrate oxidation rates, remained unaffected. Furthermore, performance outcomes and gastrointestinal discomfort were not affected, but further research is required to offer specific guidelines on supplementing isomaltulose in a performance setting.

A 2019 study in endurance athletes (n=10) on a cycle ergometer found that fat oxidation was significantly different between the isomaltulose and sucrose groups at 3 min (p<0.05) and carbohydrate oxidation was significantly different at 3, 6, and 12 min (p<0.05). The isomaltulose group's blood glucose concentrations were significantly lower than those of the sucrose group at several time points (p<0.05).

A study published in the International Journal of Sport Nutrition and Exercise Metabolism (2015) introduced an important cautionary finding. Nine male cyclists participated during three trials of 2-h steady-state exercise (60% Wmax) followed by a 16 km time trial while ingesting 63 g·h^-1 of either fructose:maltodextrin or isomaltulose or placebo-flavored water. During steady-state exercise, isomaltulose and placebo similarly increased plasma non-esterified fatty acid concentration and fat oxidation while decreasing carbohydrate oxidation compared with the fructose:maltodextrin drink. However, time-trial performance was substantially slower with isomaltulose compared with the fructose:maltodextrin drink. Additionally, ratings of stomach cramps and bloating increased progressively with isomaltulose under these high-dose conditions, and ingesting isomaltulose at a continuous high frequency to meet the recommended carbohydrate replacement dose results in severe gastrointestinal symptoms during prolonged or high intensity exercise.

Evidence summary (sports): Multiple studies confirm that isomaltulose lowers postprandial blood glucose and insulin during exercise relative to sucrose or high-GI carbohydrates, and several report associated increases in fat oxidation. However, evidence for direct performance benefits (time-trial improvement, time to exhaustion) is mixed and in some studies absent or negative, particularly at high ingestion rates. Study populations have been relatively small and predominantly male. Overall evidence strength for fat oxidation is moderate; for direct performance enhancement it is weak to mixed.

Isomaltulose was tolerated well in sports studies, even when consumed in high amounts common in sports (e.g., up to 125 g), and it has shown to give sufficient carbohydrate energy for endurance exercise at high intensity levels. The exception noted above (high continuous dosing) underscores the importance of dosing pattern.

4.4 Weight Management and Body Composition

A randomized, double-blind, controlled 12-week trial investigated the effects of an energy-reduced diet containing isomaltulose versus sucrose on body weight. Sixty-four healthy overweight/obese adults were allocated to consume either 40 g/day isomaltulose or sucrose added to an energy-reduced diet for 12 weeks. Anthropometric measurements, body composition, and energy metabolism were assessed at baseline and after 4, 8, and 12 weeks. Fifty participants (age: 40.7 ± 11.7 y; BMI: 29.4 ± 2.7 kg/m²) completed the study. During the 12 weeks, both groups significantly lost weight (p < 0.001), which was more pronounced following isomaltulose (−3.2 ± 2.9 vs. −2.1 ± 2.6 kg; p = 0.258). Moreover, for participants in the isomaltulose group, this was accompanied by a significant reduction in fat mass (ISO: −1.9 ± 2.5%, p = 0.005; SUC: −0.9 ± 2.6%, p = 0.224). The results suggest that isomaltulose in exchange for sucrose may help to facilitate body weight reduction, lower postprandial respiratory quotient associated with higher fat oxidation, and reduce energy intake.

Evidence summary (weight management): This single 12-week RCT provides preliminary human evidence for modestly greater fat mass reduction with isomaltulose compared to sucrose under hypocaloric conditions. The between-group weight difference did not reach statistical significance (p = 0.258), though fat mass reduction in the isomaltulose group was significant. Replication in larger trials is needed.

4.5 Cognitive Performance

The rate of glucose supply from dietary carbohydrates can affect cognitive performance, with effects on mood and memory having been shown in several studies that compared isomaltulose with higher glycaemic carbohydrates taken at breakfast, showing improvements in mood and memory in healthy children, middle-aged adults, and aged adults.

A PMC-indexed review (Gilsenan et al., published in Nutrients and summarized in the PMC update of clinical trials) states: In both children, and older and middle-aged adults with good glucose tolerance, lowering the GI and glycemic load of breakfast by the use of isomaltulose improved cognition later in the morning.

A study examining children aged 5–6 years found that focused attention and numerical memory declined across the morning, but performance after a drink containing isomaltulose was better than after a higher-GI comparator. However, adult studies present a more ambiguous picture. One study compared the effects of isomaltulose and sucrose in young adults. Although isomaltulose produced a lower blood glucose profile than sucrose, there were no differences in memory or psychomotor performance. It may be critical that the final testing session took place 115 min after the drink, when greater effects have been reported after 210 min.

Evidence summary (cognition): Preliminary human evidence — particularly in children and older adults — suggests modest improvements in morning cognitive function when breakfast glycemic load is lowered using isomaltulose. Adult evidence is inconsistent. Study populations are small and methodologies heterogeneous; this area requires larger, well-controlled trials.

4.6 Dental Health

Isomaltulose is "kind to teeth." Fermentation of carbohydrates by bacteria in the mouth (especially on the teeth) is responsible for the formation of dental plaque and oral acids. The acid initiates tooth demineralisation and tooth decay (dental caries). Isomaltulose largely resists fermentation by oral bacteria and is the first carbohydrate of its kind with negligible acid production on teeth, as shown by pH telemetry.

The evidence is strong and provides the basis for "kind to teeth" claims approved by both the Food and Drug Administration in the USA and European authorities following a positive opinion from the European Food Safety Authority. Consequently, acid production from isomaltulose in the mouth is too slow to promote tooth decay.

Evidence summary (dental): This is among the best-characterized benefits of isomaltulose. Non-cariogenic properties have been validated by pH telemetry and form the basis of regulatory health claims in both the EU and USA. Evidence strength is strong.

4.7 Prebiotic and Gut Microbiota Effects

In vitro experiments have indicated prebiotic activity of isomaltulose, which stimulates the growth of probiotics and the production of short chain fatty acids (SCFAs). However, the absence of in vivo trials in humans undermines these results.

A rat study (Sprague-Dawley model, 12 animals, 5 weeks, 10% isomaltulose in drinking water) provided in vivo data: 16S rRNA sequencing showed that ingestion of isomaltulose increased the abundances of beneficial microbiota, such as Faecalibacterium and Phascolarctobacterium, and decreased levels of pathogens, including Shuttleworthia. Bacterial functional prediction showed that isomaltulose affected gut microbial functionalities, including secondary bile acid biosynthesis. Targeted metabolomics demonstrated that isomaltulose supplementation enhanced cholic acid concentration and reduced levels of secondary bile acids. Moreover, the concentrations of propionate and butyrate were elevated in the rats administered with isomaltulose. This work suggests that isomaltulose modulates gut microbiota and the production of SCFAs and secondary bile acids in rats, providing a scientific basis for the use of isomaltulose as a prebiotic.

While the above in-vitro studies suggest potential prebiotic and synbiotic activity of isomaltulose, there is a definite need for more evidence from metabolic studies.

Evidence summary (gut microbiota): Preliminary evidence from in vitro and animal studies (rodents) suggests possible prebiotic activity. No controlled human trials specifically examining isomaltulose's effects on gut microbiota composition have been published as of the most recent literature reviews. Evidence is preliminary and insufficient to draw clinical conclusions.

4.8 Pregnancy and Fertility

Clinical reviews have discussed recent reports on potential beneficial effects of isomaltulose in weight-loss maintenance and pregnancy. With regard to body composition and pregnancy outcome, hyperinsulinemia induced by a high-GI diet may lead to higher fat storage at a positive energy balance. These observations have motivated investigations into whether replacing sucrose with isomaltulose in gestational diets could favorably modify pregnancy metabolic outcomes, but as of available published literature, human clinical trial evidence in pregnant women specifically is very limited.

Animal safety data on reproduction are available: an embryotoxicity/teratogenicity study of isomaltulose was conducted in Wistar rats. Groups of 24 mated females were fed diets containing isomaltulose at levels of 0, 2.5, 5 and 10% from day 0 to day 21 of pregnancy. No maternal toxicity occurred and no effects on reproductive performance, nor on embryonic or foetal development, including visceral and skeletal examination, were seen in any of the groups fed isomaltulose. The dietary level of 10% isomaltulose was equivalent to about 7 g/kg body weight/day.

5. Body Systems and Health Areas

Metabolic / Endocrine System: Postprandial glucose regulation, insulin secretion modulation, incretin (GLP-1, GIP) response, fat oxidation, glycogen sparing, management of type 2 diabetes mellitus.
Musculoskeletal / Exercise Physiology: Sustained carbohydrate energy delivery, substrate utilization during endurance exercise, body composition (fat mass).
Oral / Dental Health: Dental caries prevention, tooth mineralization maintenance.
Central Nervous System / Cognition: Morning cognitive performance, mood and memory via steady glucose supply to the brain.
Gastrointestinal System: Full digestion and absorption in the small intestine; proposed prebiotic modulation of gut microbiota composition and SCFA production (evidence currently from animal/in vitro data only).
Clinical Nutrition: Enteral and oral nutritional feeds for glycemic control in disease-specific nutrition.

6. Dosage Forms and Dosages Reported in Studies

Isomaltulose is delivered orally and is formulated in the following ways across published research and regulatory documents:

Dissolved in water (acute challenge studies): Typically 50 g dissolved in water, consumed after overnight fast, as used in most glycemic response RCTs included in the 2022 systematic review.
Exercise studies — pre-exercise bolus: 50 g isomaltulose was administered before a 70-min constant load trial.
Exercise studies — continuous ingestion during exercise: 63 g·h^-1 during 2-h steady-state cycling and a subsequent time trial.
Sports studies — large bolus: Up to 125 g consumed in a sports context without reported adverse effects.
Weight management (12-week RCT): 40 g/day added to an energy-reduced diet for 12 weeks.
Infant formula: A randomised, double-blind, controlled four-week study in infants from 4 to 8 months of age assessed follow-on formula containing 2.1 g/100 mL isomaltulose.
Tolerable bolus dose (regulatory assessment): There exist clear data to support the tolerability of isomaltulose at doses of up to 1 g/kg body weight (~70 g isomaltulose) administered under bolus dosing conditions, and higher total daily intakes are expected to be well tolerated, especially when administered throughout the day.

7. Safety Considerations and Regulatory Status

Regulatory Approvals

Isomaltulose is generally recognized as safe (GRAS) by the U.S. Food and Drug Administration, is approved as a novel food by the European Commission, and in Japan has the status FOSHU (Food for Specific Health Use).

The EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) conducted a 2024 formal safety review: the information provided on the manufacturing process, composition and specifications is sufficient and does not raise safety concerns. No absorption, distribution, metabolism and excretion (ADME) or toxicological data were provided for the novel food. Instead, safety was assessed based on literature data available on isomaltulose and mixtures of isomaltulose and trehalulose. Considering the nature, compositional characterisation and production process, the Panel considered that such data were sufficient to conclude that the novel food is as safe as sucrose.

Tolerance at Various Dose Levels

The Food Safety Authority of Ireland concluded that "since ingested isomaltulose is rapidly hydrolysed and absorbed as glucose and fructose, several high doses could be consumed in the course of a day without risk of intestinal side effects." Daily doses of 1.0–1.3 g/kg body weight per day are expected to be as well tolerated as corresponding doses of sucrose in adults and children.

Gastrointestinal Effects at High Exercise Doses

Although isomaltulose is well tolerated at most doses, when ingested at a continuous high frequency during prolonged moderate-to-heavy exercise (63 g·h^-1), isomaltulose was associated with progressive increases in ratings of stomach cramps and bloating, and time-trial performance was substantially slower compared with a fructose:maltodextrin drink. These gastrointestinal effects at high continuous exercise dosing should be distinguished from ordinary dietary or bolus consumption.

Caloric Content

As a nutritive carbohydrate, isomaltulose adds to the caloric content of a product with 4 kcal/g. It is not a reduced-calorie sweetener; its health advantages relate to the rate and metabolic context of energy release, not to caloric reduction.

Reproductive Safety (Animal Data)

No maternal toxicity occurred and no effects on reproductive performance, nor on embryonic or foetal development, were seen in rats fed up to 10% dietary isomaltulose (equivalent to approximately 7 g/kg body weight/day) throughout pregnancy.

Health Claim Status

The European Food Safety Authority (EFSA) has confirmed the benefits of isomaltulose for dental health: "Consumption of food and drinks containing isomaltulose instead of sugar contributes to the maintenance of tooth mineralization." This is a formally approved health claim.

An EFSA opinion evaluating isomaltulose's relationship to "normal energy-yielding metabolism" under Article 13(5) of Regulation (EC) No 1924/2006 has also been issued, though the opinion does not constitute, and cannot be construed as, an authorisation for the marketing of isomaltulose, a positive assessment of its safety, nor a decision on whether isomaltulose is, or is not, classified as a foodstuff.

Evidence Gaps and Limitations

Across all health domains, several limitations recur in the published literature: many studies are short-term and small in size; exercise performance studies have been conducted predominantly in healthy adult males; evidence for prebiotic effects remains animal- and in vitro-based; and the optimal dose, timing, and frequency for specific health outcomes remain subjects of ongoing investigation. There is a need for more clinical trials to know its efficacy and bioavailability in various food products.

References

Health Conditions

Health conditions that Isomaltulose may help support.

No conditions available.

Body Systems

Body systems that Isomaltulose may help support.

No body systems available.